Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
about
Syndromic gastrointestinal stromal tumorsMolecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromesNCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del)Neoplasms associated with germline and somatic NF1 gene mutationsThe NF1 gene revisited - from bench to bedside.Adjuvant treatment of GIST: patient selection and treatment strategies.Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.MDCT features of succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumours.Succinate Dehydrogenase Subunit B (SDHB) Is Expressed in Neurofibromatosis 1-Associated Gastrointestinal Stromal Tumors (Gists): Implications for the SDHB Expression Based Classification of GistsGiant gastrointestinal stromal tumor presenting as a palpable abdominal mass: an unusual presentation.Advances in sarcoma genomics and new therapeutic targets.Gastrointestinal manifestations of neurofibromatosis type 1 (Recklinghausen's disease): clinicopathological spectrum with pathogenetic considerations.The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations.Gastrointestinal stromal tumors in Japanese patients with neurofibromatosis type I.Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.Gastrointestinal stromal tumors associated with neurofibromatosis 1: a single centre experience and systematic review of the literature including 252 casesMAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.How best to manage gastrointestinal stromal tumor.The GIST paradigm: lessons for other kinase-driven cancers.Current and emerging pharmacological treatments for gastrointestinal stromal tumour.Adjuvant therapy of gastrointestinal stromal tumors (GIST).Surgical management of localized soft tissue tumors.Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy.Gastrointestinal stromal tumor with KIT mutation in neurofibromatosis type 1.Neurofibromatosis type 1-associated wild-type gastrointestinal stromal tumor treated with anti-IGF-1R monoclonal antibody.Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs.Rapid diagnosis of combined multifocal gastrointestinal stromal tumours and coeliac disease in a patient with type 1 neurofibromatosis.The Scandinavian Sarcoma Group: 30 years' experience.Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs.What is New in Gastrointestinal Stromal Tumor?[Advanced gastrointestinal stromal tumors : What role does surgery currently play in multimodal concepts?].Phaeochromocytoma, neurofibromatosis and gastrointestinal stromal tumour: just a random event?69-jähriger Patient mit chronischen Bauchschmerzen und Anämie bei Neurofibromatose
P2860
Q26738882-8CC23EFD-39FE-49CF-8672-BB46655548B8Q30245586-4CDB6F8A-866B-4AAD-81BC-7BDBA4B6FAE1Q30475253-49AE19C0-369E-46E6-B6B5-55A03AD406A1Q33921067-1B107355-BB51-4C61-954A-DEA1405E98B9Q34036409-D4088A8B-1763-45E8-8F63-B5F5324F4D30Q34125947-BD1BC152-C3D8-4B1D-89A1-D7A9A6532335Q34227509-823CD934-D843-4429-8F03-88BA6C9C5F8FQ34270274-4CAEAF83-18C7-468E-AD7C-A178FA3CF750Q34300784-CD1E16E1-2395-498F-888E-C7DC38891482Q34392125-07CB4897-A268-472E-A0CC-BF1B96B46098Q34771877-6FDA2C21-3896-4548-9706-14BE600EC612Q35440087-A6E94A81-2E52-4F6C-A465-7A229D5A9236Q35993346-4BCA9F7E-55D9-4CB4-9576-9B24136602A5Q36358065-6AC91155-6957-41E2-B201-184240830312Q36509363-A9122426-7838-40E7-977D-B9395F440CB2Q36936557-18DBC83D-3C52-4E78-9D47-4A20B9600775Q37220191-C2376FD0-70EA-4FF7-8527-B1A5101AB483Q37413027-4B276080-56D8-4B3C-A3D0-6B7439D0AFFCQ37692151-5246DB13-B77E-4DFA-927C-BB7C614A07E1Q37743051-736DF0AE-1860-4C55-8D32-4AE9DA1D283DQ37815140-41542C08-48F2-43AF-8F9E-EBF1DEC1053AQ37841551-E1BEC9D6-A271-4A25-B5BE-2D6CFA3584D8Q38022443-2F0A09D0-8F88-4547-8C58-072806735B12Q38206158-8FA25A14-EC05-4B2F-B3EA-30299C5DBA15Q38399838-4EC08FA8-1827-4C48-8EB5-5911FB7CE229Q39217262-9FB9F24A-DDF2-4485-898C-D71BE958A73CQ39843575-4F5E97E7-6E46-4B1E-8F64-6D32ACCC8745Q40804607-A5B1642B-56AA-4276-B1BD-AEC8EDB257F6Q42114033-B3656D0C-18F6-4CEF-9672-177EAA63FA3EQ43589203-2DEB8197-3F47-4BC3-8A74-E89FC1F10E37Q48141393-27303521-CC02-4504-B513-82379D190710Q50575961-FED21263-A232-4226-A615-E29B853A3423Q53121873-4AC8E1CA-4D60-486D-A333-ED35BD635D9DQ57500379-B3CDC273-F721-49E8-93D6-0F5FDFFC69BBQ58011646-0BAC4EA2-49C5-4F92-860A-EE0BF3569382
P2860
Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Therapeutic consequences from ...... d by neurofibromatosis type 1.
@en
Therapeutic consequences from ...... d by neurofibromatosis type 1.
@nl
type
label
Therapeutic consequences from ...... d by neurofibromatosis type 1.
@en
Therapeutic consequences from ...... d by neurofibromatosis type 1.
@nl
prefLabel
Therapeutic consequences from ...... d by neurofibromatosis type 1.
@en
Therapeutic consequences from ...... d by neurofibromatosis type 1.
@nl
P2093
P1476
Therapeutic consequences from ...... d by neurofibromatosis type 1.
@en
P2093
Chiara Mussi
Eva Wardelmann
Hans-Ulrich Schildhaus
Peter Hohenberger
P304
P356
10.1158/1078-0432.CCR-08-0086
P407
P577
2008-07-01T00:00:00Z